

Covid-19 Impact on Neuroprotective Drugs Market, Global Research Reports 2020-2021

<https://marketpublishers.com/r/C926C8B09FA6EN.html>

Date: June 2020

Pages: 94

Price: US\$ 3,250.00 (Single User License)

ID: C926C8B09FA6EN

Abstracts

This report covers market size and forecasts of Neuroprotective Drugs, including the following market information:

Global Neuroprotective Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US\$ Million) & (MT)

Global Neuroprotective Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US\$ Million) & (MT)

Global Neuroprotective Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US\$ Million) & (MT)

Global Neuroprotective Drugs Market Size by Company, 2019- 2020 (quarterly data), (US\$ Million) & (MT)

Key market players

Major competitors identified in this market include Genervon Biopharmaceuticals (Canada), NeuroVive Pharmaceutical (Sweden), Ceregene (USA), BHRPharma (Thailand), Neuren Pharmaceuticals (Australia), Allon therapeutics (Canada), Bionure Inc. (USA), etc.

Based on the Region:

Asia-Pacific (China, Japan, South Korea, India and ASEAN)

North America (US and Canada)

Europe (Germany, France, UK and Italy)

Rest of World (Latin America, Middle East & Africa)

Based on the Type:

Cholinesterase inhibitors

Anti-inflammatory

Others

Based on the Application:

Alzheimer's disease

Parkinson's disease

Others

Contents

- 1.1 Research Scope
- 1.2 Market Segmentation
- 1.3 Research Objectives
- 1.4 Research Methodology
 - 1.4.1 Research Process
 - 1.4.2 Data Triangulation
 - 1.4.3 Research Approach
 - 1.4.4 Base Year
- 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
 - 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
 - 1.5.2 Covid-19 Impact: Commodity Prices Indices
 - 1.5.3 Covid-19 Impact: Global Major Government Policy
- 1.6 The Covid-19 Impact on Neuroprotective Drugs Industry
- 1.7 COVID-19 Impact: Neuroprotective Drugs Market Trends

2 GLOBAL NEUROPROTECTIVE DRUGS QUARTERLY MARKET SIZE ANALYSIS

- 2.1 Neuroprotective Drugs Business Impact Assessment - COVID-19
 - 2.1.1 Global Neuroprotective Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
 - 2.1.2 Global Neuroprotective Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.2 Global Neuroprotective Drugs Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
 - 2.3.1 Drivers
 - 2.3.2 Restraints
 - 2.3.3 Opportunities
 - 2.3.4 Challenges

3 QUARTERLY COMPETITIVE ASSESSMENT, 2020

- 3.1 Global Neuroprotective Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
- 3.2 Global Neuroprotective Drugs Factory Price by Manufacturers
- 3.3 Location of Key Manufacturers Neuroprotective Drugs Manufacturing Factories and Area Served

- 3.4 Date of Key Manufacturers Enter into Neuroprotective Drugs Market
- 3.5 Key Manufacturers Neuroprotective Drugs Product Offered
- 3.6 Mergers & Acquisitions, Expansion Plans

4 IMPACT OF COVID-19 ON NEUROPROTECTIVE DRUGS SEGMENTS, BY TYPE

- 4.1 Introduction
 - 1.4.1 Cholinesterase inhibitors
 - 1.4.2 Anti-inflammatory
 - 1.4.3 Others
- 4.2 By Type, Global Neuroprotective Drugs Market Size, 2019-2021
 - 4.2.1 By Type, Global Neuroprotective Drugs Market Size by Type, 2020-2021
 - 4.2.2 By Type, Global Neuroprotective Drugs Price, 2020-2021

5 IMPACT OF COVID-19 ON NEUROPROTECTIVE DRUGS SEGMENTS, BY APPLICATION

- 5.1 Overview
 - 5.5.1 Alzheimer's disease
 - 5.5.2 Parkinson's disease
 - 5.5.3 Others
- 5.2 By Application, Global Neuroprotective Drugs Market Size, 2019-2021
 - 5.2.1 By Application, Global Neuroprotective Drugs Market Size by Application, 2019-2021
 - 5.2.2 By Application, Global Neuroprotective Drugs Price, 2020-2021

6 GEOGRAPHIC ANALYSIS

- 6.1 Introduction
- 6.2 North America
 - 6.2.1 Macroeconomic Indicators of US
 - 6.2.2 US
 - 6.2.3 Canada
- 6.3 Europe
 - 6.3.1 Macroeconomic Indicators of Europe
 - 6.3.2 Germany
 - 6.3.3 France
 - 6.3.4 UK
 - 6.3.5 Italy

6.4 Asia-Pacific

6.4.1 Macroeconomic Indicators of Asia-Pacific

6.4.2 China

6.4.3 Japan

6.4.4 South Korea

6.4.5 India

6.4.6 ASEAN

6.5 Rest of World

6.5.1 Latin America

6.5.2 Middle East and Africa

7 COMPANY PROFILES

7.1 Genervon Biopharmaceuticals (Canada)

7.1.1 Genervon Biopharmaceuticals (Canada) Business Overview

7.1.2 Genervon Biopharmaceuticals (Canada) Neuroprotective Drugs Quarterly Production and Revenue, 2020

7.1.3 Genervon Biopharmaceuticals (Canada) Neuroprotective Drugs Product Introduction

7.1.4 Genervon Biopharmaceuticals (Canada) Response to COVID-19 and Related Developments

7.2 NeuroVive Pharmaceutical (Sweden)

7.2.1 NeuroVive Pharmaceutical (Sweden) Business Overview

7.2.2 NeuroVive Pharmaceutical (Sweden) Neuroprotective Drugs Quarterly Production and Revenue, 2020

7.2.3 NeuroVive Pharmaceutical (Sweden) Neuroprotective Drugs Product Introduction

7.2.4 NeuroVive Pharmaceutical (Sweden) Response to COVID-19 and Related Developments

7.3 Ceregene (USA)

7.3.1 Ceregene (USA) Business Overview

7.3.2 Ceregene (USA) Neuroprotective Drugs Quarterly Production and Revenue, 2020

7.3.3 Ceregene (USA) Neuroprotective Drugs Product Introduction

7.3.4 Ceregene (USA) Response to COVID-19 and Related Developments

7.4 BHRPharma (Thailand)

7.4.1 BHRPharma (Thailand) Business Overview

7.4.2 BHRPharma (Thailand) Neuroprotective Drugs Quarterly Production and Revenue, 2020

7.4.3 BHRPharma (Thailand) Neuroprotective Drugs Product Introduction

- 7.4.4 BHRPharma (Thailand) Response to COVID-19 and Related Developments
- 7.5 Neuren Pharmaceuticals (Australia)
 - 7.5.1 Neuren Pharmaceuticals (Australia) Business Overview
 - 7.5.2 Neuren Pharmaceuticals (Australia) Neuroprotective Drugs Quarterly Production and Revenue, 2020
 - 7.5.3 Neuren Pharmaceuticals (Australia) Neuroprotective Drugs Product Introduction
 - 7.5.4 Neuren Pharmaceuticals (Australia) Response to COVID-19 and Related Developments
- 7.6 Allon therapeutics (Canada)
 - 7.6.1 Allon therapeutics (Canada) Business Overview
 - 7.6.2 Allon therapeutics (Canada) Neuroprotective Drugs Quarterly Production and Revenue, 2020
 - 7.6.3 Allon therapeutics (Canada) Neuroprotective Drugs Product Introduction
 - 7.6.4 Allon therapeutics (Canada) Response to COVID-19 and Related Developments
- 7.7 Bionure Inc. (USA)
 - 7.7.1 Bionure Inc. (USA) Business Overview
 - 7.7.2 Bionure Inc. (USA) Neuroprotective Drugs Quarterly Production and Revenue, 2020
 - 7.7.3 Bionure Inc. (USA) Neuroprotective Drugs Product Introduction
 - 7.7.4 Bionure Inc. (USA) Response to COVID-19 and Related Developments

8 SUPPLY CHAIN AND SALES CHANNELS ANALYSIS

- 8.1 Neuroprotective Drugs Supply Chain Analysis
 - 8.1.1 Neuroprotective Drugs Supply Chain Analysis
 - 8.1.2 Covid-19 Impact on Neuroprotective Drugs Supply Chain
- 8.2 Distribution Channels Analysis
 - 8.2.1 Neuroprotective Drugs Distribution Channels
 - 8.2.2 Covid-19 Impact on Neuroprotective Drugs Distribution Channels
 - 8.2.3 Neuroprotective Drugs Distributors
- 8.3 Neuroprotective Drugs Customers

9 KEY FINDINGS

10 APPENDIX

- 10.1 About Us
- 10.2 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Overview of the World Economic Outlook Projections

Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)

Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 7. Covid-19 Impact: Global Major Government Policy

Table 8. The Covid-19 Impact on Neuroprotective Drugs Assessment

Table 9. COVID-19 Impact: Neuroprotective Drugs Market Trends

Table 10. COVID-19 Impact Global Neuroprotective Drugs Market Size

Table 11. Global Neuroprotective Drugs Market Size Pre-COVID-19 and Post-COVID-19 Comparison, 2015-2026 (MT)

Table 12. Global Neuroprotective Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/Kg)

Table 13. Global Neuroprotective Drugs Quarterly Market Size, 2020 (US\$ Million) & (MT)

Table 14. Global Neuroprotective Drugs Market Size, Pre-COVID-19 and Post-COVID-19 Quarterly Comparison, 2020-2021 (US\$ Million)

Table 15. Global Neuroprotective Drugs Market Size, Pre-COVID-19 and Post-COVID-19 Quarterly Comparison, 2020-2021 (MT)

Table 16. Global Neuroprotective Drugs Market Growth Drivers

Table 17. Global Neuroprotective Drugs Market Restraints

Table 18. Global Neuroprotective Drugs Market Opportunities

Table 19. Global Neuroprotective Drugs Market Challenges

Table 20. Key Manufacturers Neuroprotective Drugs Quarterly Revenue, 2019 VS 2020 (US\$ Million)

Table 21. Top Manufacturers, Neuroprotective Drugs Market Size, 2019 (MT) & (US\$ Million)

Table 22. Neuroprotective Drugs Factory Price by Manufacturers 2020 (USD/Kg)

Table 23. Location of Key Manufacturers Neuroprotective Drugs Manufacturing Plants

Table 24. Key Manufacturers Neuroprotective Drugs Market Served

Table 25. Date of Key Manufacturers Enter into Neuroprotective Drugs Market

Table 26. Key Manufacturers Neuroprotective Drugs Product Type

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Neuroprotective Drugs Market Size by Type, 2020, (US\$ Million)

Table 29. Global Neuroprotective Drugs Market Size by Type, 2020 (MT)

Table 30. Global Neuroprotective Drugs Price: by Type, 2020-2021 (USD/Kg)

Table 31. Global Neuroprotective Drugs Market Size by Application: 2020-2021 (US\$ Million)

Table 32. Global Neuroprotective Drugs Market Size by Application, 2020-2021 (MT)

Table 33. Global Neuroprotective Drugs Price: by Application, 2020-2021 (USD/Kg)

Table 34. Global Neuroprotective Drugs Market Size by Region, 2019-2021 (US\$ Million)

Table 35. Global Neuroprotective Drugs Market Size by Region, 2019-2021 (MT)

Table 36. By Country, North America Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million)

Table 37. By Country, North America Neuroprotective Drugs Market Size, 2019-2021 (MT)

Table 38. US Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)

Table 39. Canada Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)

Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)

Table 41. By Country, Europe Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million)

Table 42. By Country, Europe Neuroprotective Drugs Market Size, 2019-2021 (MT)

Table 43. Germany Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)

Table 44. France Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)

Table 45. UK Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)

Table 46. Italy Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)

Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)

Table 48. By Region, Asia-Pacific Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million)

Table 49. By Region, Asia-Pacific Neuroprotective Drugs Market Size, 2019-2021 (MT)

Table 50. China Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)

Table 51. Japan Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)

Table 52. South Korea Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)

- Table 53. India Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)
- Table 54. ASEAN Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)
- Table 55. Latin America Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)
- Table 56. Middle East and Africa Neuroprotective Drugs Market Size, 2019-2021 (US\$ Million) & (MT)
- Table 57. Genervon Biopharmaceuticals (Canada) Business Overview
- Table 58. Genervon Biopharmaceuticals (Canada) Neuroprotective Drugs Production (MT), Revenue (US\$ Million), Price (USD/Kg) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
- Table 59. Genervon Biopharmaceuticals (Canada) Neuroprotective Drugs Product
- Table 60. Genervon Biopharmaceuticals (Canada) Response to COVID-19 and Related Developments
- Table 61. NeuroVive Pharmaceutical (Sweden) Business Overview
- Table 62. NeuroVive Pharmaceutical (Sweden) Neuroprotective Drugs Production (MT), Revenue (US\$ Million), Price (USD/Kg) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
- Table 63. NeuroVive Pharmaceutical (Sweden) Neuroprotective Drugs Product
- Table 64. NeuroVive Pharmaceutical (Sweden) Response to COVID-19 and Related Developments
- Table 65. Ceregene (USA) Business Overview
- Table 66. Ceregene (USA) Neuroprotective Drugs Production (MT), Revenue (US\$ Million), Price (USD/Kg) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
- Table 67. Ceregene (USA) Neuroprotective Drugs Product
- Table 68. Ceregene (USA) Response to COVID-19 and Related Developments
- Table 69. BHRPharma (Thailand) Business Overview
- Table 70. BHRPharma (Thailand) Neuroprotective Drugs Production (MT), Revenue (US\$ Million), Price (USD/Kg) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
- Table 71. BHRPharma (Thailand) Neuroprotective Drugs Product
- Table 72. BHRPharma (Thailand) Response to COVID-19 and Related Developments
- Table 73. Neuren Pharmaceuticals (Australia) Business Overview
- Table 74. Neuren Pharmaceuticals (Australia) Neuroprotective Drugs Production (MT), Revenue (US\$ Million), Price (USD/Kg) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
- Table 75. Neuren Pharmaceuticals (Australia) Neuroprotective Drugs Product
- Table 76. Neuren Pharmaceuticals (Australia) Response to COVID-19 and Related Developments
- Table 77. Allon therapeutics (Canada) Business Overview
- Table 78. Allon therapeutics (Canada) Neuroprotective Drugs Production (MT),

Revenue (US\$ Million), Price (USD/Kg) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 79. Allon therapeutics (Canada) Neuroprotective Drugs Product

Table 80. Allon therapeutics (Canada) Response to COVID-19 and Related Developments

Table 81. Bionure Inc. (USA) Business Overview

Table 82. Bionure Inc. (USA) Neuroprotective Drugs Production (MT), Revenue (US\$ Million), Price (USD/Kg) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 83. Bionure Inc. (USA) Neuroprotective Drugs Product

Table 84. Bionure Inc. (USA) Response to COVID-19 and Related Developments

Table 85. Neuroprotective Drugs Distributors List

Table 86. Neuroprotective Drugs Customers List

Table 87. Covid-19 Impact on Neuroprotective Drugs Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Neuroprotective Drugs Product Picture
- Figure 2. Neuroprotective Drugs Market Segmentation
- Figure 3. Research Objectives
- Figure 4. Research Process
- Figure 5. Data Triangulation
- Figure 6. Research Approach
- Figure 7. Commodity Prices-Metals Price Indices
- Figure 8. Commodity Prices- Precious Metal Price Indices
- Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
- Figure 10. Commodity Prices- Food and Beverage Price Indices
- Figure 11. Commodity Prices- Fertilizer Price Indices
- Figure 12. Commodity Prices- Energy Price Indices
- Figure 13. G20+: Economic Policy Responses to COVID-19
- Figure 14. Global Neuroprotective Drugs Market Size, Pre-COVID-19 and Post-COVID-19 Comparison, 2015-2026 (US\$ Million)
- Figure 15. Global Neuroprotective Drugs Market Size, Pre-COVID-19 and Post-COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
- Figure 16. Global Neuroprotective Drugs Market Size, Quarterly Growth, 2020-2021 (%)
- Figure 17. Global Neuroprotective Drugs Market Size, Market Share by Type, 2019 VS 2020 (%)
- Figure 18. Global Neuroprotective Drugs Market Size, Market Share by Application, 2019 VS 2020 (%)
- Figure 19. Global Neuroprotective Drugs Market Size Market Share by Region, 2019 VS 2020 (%)
- Figure 20. United States Composite PMI and GDP
- Figure 21. Eurozone Composite PMI and GDP
- Figure 22. Eurozone Core v. Periphery PMI Output Indices
- Figure 23. Core v. Periphery PMI Employment Indices
- Figure 24. UK Composite PMI and GDP
- Figure 25. Caixin China Composite Output Index
- Figure 26. Caixin China General Services Business Activity Index
- Figure 27. Japan Composite Output Index
- Figure 28. South Korea Manufacturing PMI
- Figure 29. India Composite Output Index
- Figure 30. ASEAN Manufacturing PMI

Figure 31. By Region, Asia-Pacific Neuroprotective Drugs Market Size Market Share, 2019-2021

I would like to order

Product name: Covid-19 Impact on Neuroprotective Drugs Market, Global Research Reports 2020-2021

Product link: <https://marketpublishers.com/r/C926C8B09FA6EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C926C8B09FA6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970